Latest Logos Global Management LP Stock Portfolio
Logos Global Management LP Performance:
2025 Q4: 30.46%YTD: 32.36%2024: -5.91%
Performance for 2025 Q4 is 30.46%, and YTD is 32.36%, and 2024 is -5.91%.
About Logos Global Management LP and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Logos Global Management LP reported an equity portfolio of $1.7 Billions as of 31 Dec, 2025.
The top stock holdings of Logos Global Management LP are RVMD, PRAX, IDYA. The fund has invested 9.6% of it's portfolio in REVOLUTION MEDICINES INC and 6.7% of portfolio in PRAXIS PRECISION MEDICINES I.
The fund managers got completely rid off AKERO THERAPEUTICS INC (AKRO), ARVINAS INC (ARVN) and PROTAGONIST THERAPEUTICS INC (PTGX) stocks. They significantly reduced their stock positions in SEPTERNA INC, CENTESSA PHARMACEUTICALS PLC (CNTA) and ACLARIS THERAPEUTICS INC (ACRS). Logos Global Management LP opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and ACADIA PHARMACEUTICALS INC (ACAD). The fund showed a lot of confidence in some stocks as they added substantially to IMMUNOVANT INC (IMVT), TANGO THERAPEUTICS INC (TNGX) and MEREO BIOPHARMA GROUP PLC (MREO).
The top stock holdings of Logos Global Management LP are RVMD, PRAX, IDYA. The fund has invested 9.6% of it's portfolio in REVOLUTION MEDICINES INC and 6.7% of portfolio in PRAXIS PRECISION MEDICINES I.
The fund managers got completely rid off AKERO THERAPEUTICS INC (AKRO), ARVINAS INC (ARVN) and PROTAGONIST THERAPEUTICS INC (PTGX) stocks. They significantly reduced their stock positions in SEPTERNA INC, CENTESSA PHARMACEUTICALS PLC (CNTA) and ACLARIS THERAPEUTICS INC (ACRS). Logos Global Management LP opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and ACADIA PHARMACEUTICALS INC (ACAD). The fund showed a lot of confidence in some stocks as they added substantially to IMMUNOVANT INC (IMVT), TANGO THERAPEUTICS INC (TNGX) and MEREO BIOPHARMA GROUP PLC (MREO).
Logos Global Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Logos Global Management LP made a return of 30.46% in the last quarter. In trailing 12 months, it's portfolio return was 32.36%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| terns pharmaceuticals inc | 30,300,000 |
| moonlake immunotherapeutics | 23,065,000 |
| acadia pharmaceuticals inc | 22,703,500 |
| cytokinetics inc | 19,062,000 |
| mirum pharmaceuticals inc | 17,772,800 |
| newamsterdam pharma company | 15,786,000 |
| kiniksa pharmaceuticals intl | 14,437,500 |
| soleno therapeutics inc | 13,890,000 |
New stocks bought by Logos Global Management LP
Additions
| Ticker | % Inc. |
|---|---|
| immunovant inc | 400 |
| tango therapeutics inc | 342 |
| mereo biopharma group plc | 270 |
| praxis precision medicines i | 200 |
| uniqure nv | 125 |
| fractyl health inc | 120 |
| biogen inc | 100 |
| dianthus therapeutics inc | 57.5 |
Additions to existing portfolio by Logos Global Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| septerna inc | -71.82 |
| centessa pharmaceuticals plc | -61.9 |
| aclaris therapeutics inc | -60.00 |
| verastem inc | -58.02 |
| kymera therapeutics inc | -48.00 |
| dyne therapeutics inc | -47.92 |
| compass therapeutics inc | -43.9 |
| jade biosciences inc | -36.8 |
Logos Global Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| arvinas inc | -47,499,000 |
| akero therapeutics inc | -56,976,000 |
| immuneering corp | -6,650,000 |
| eupraxia pharmaceuticals inc | -5,310,000 |
| keros therapeutics inc | -13,447,000 |
| esperion therapeutics inc ne | -1,987,500 |
| pepgen inc | -3,465,000 |
| astria therapeutics inc | -3,640,000 |
Logos Global Management LP got rid off the above stocks
Sector Distribution
Logos Global Management LP has about 79.6% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 79.6 |
| Others | 20.4 |
Market Cap. Distribution
Logos Global Management LP has about 17.6% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- SMALL-CAP
- UNALLOCATED
- LARGE-CAP
| Category | % |
|---|---|
| MID-CAP | 38.1 |
| SMALL-CAP | 21.9 |
| UNALLOCATED | 20.4 |
| LARGE-CAP | 17.6 |
Stocks belong to which Index?
About 58.5% of the stocks held by Logos Global Management LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
- S&P 500
| Index | % |
|---|---|
| RUSSELL 2000 | 56.2 |
| Others | 41.5 |
| S&P 500 | 2.3 |
Logos Global Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Logos Global Management LP
Logos Global Management LP has 64 stocks in it's portfolio. About 45.5% of the portfolio is in top 10 stocks. QURE proved to be the most loss making stock for the portfolio. RVMD was the most profitable stock for Logos Global Management LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACAD | acadia pharmaceuticals inc | 1.37 | 850,000 | 22,703,500 | new | |||
| ACLX | arcellx inc | 0.45 | 115,000 | 7,498,000 | reduced | -30.3 | ||
| ACRS | aclaris therapeutics inc | 0.11 | 600,000 | 1,806,000 | reduced | -60.00 | ||
| AKRO | akero therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AMLX | amylyx pharmaceuticals inc | 0.69 | 950,000 | 11,476,000 | reduced | -34.48 | ||
| ARVN | arvinas inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTE | jade biosciences inc | 0.37 | 395,000 | 6,094,850 | reduced | -36.8 | ||
| BIIB | biogen inc | 2.13 | 200,000 | 35,198,000 | added | 100 | ||
| CDTX | cidara therapeutics inc | 4.14 | 310,000 | 68,475,900 | reduced | -17.33 | ||
| CLDX | celldex therapeutics inc new | 0.57 | 350,000 | 9,506,000 | new | |||
| CMPX | compass therapeutics inc | 0.37 | 1,150,000 | 6,175,500 | reduced | -43.9 | ||
| CNTA | centessa pharmaceuticals plc | 0.30 | 200,000 | 5,002,000 | reduced | -61.9 | ||
| COGT | cogent biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRVS | corvus pharmaceuticals inc | 0.23 | 500,000 | 3,850,000 | new | |||
| CYTK | cytokinetics inc | 1.15 | 300,000 | 19,062,000 | new | |||
| DAWN | day one biopharmaceuticals i | 0.17 | 300,000 | 2,796,000 | new | |||
| DBVT | dbv technologies s a | 0.03 | 25,000 | 479,250 | new | |||
| DSGN | design therapeutics inc | 1.42 | 2,500,000 | 23,450,000 | reduced | -31.6 | ||
| DYN | dyne therapeutics inc | 1.48 | 1,250,000 | 24,450,000 | reduced | -47.92 | ||